Compare Stocks: JAGX, CANF, CDT, and SXTC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CANF Can-Fite BioPharma	$3.40 +0.9%	$3.33	$2.56 ▼ $13.40	$2.23M	1.11	988,726 shs	23,944 shs
CDT CDT Equity	$1.69 -10.1%	$4.06	$1.62 ▼ $2,739.80	$1.33M	1.52	97,100 shs	485,652 shs
JAGX Jaguar Animal Health	$0.81 -6.4%	$1.57	$0.73 ▼ $85.40	$490K	-0.06	191,029 shs	159,927 shs
SXTC China SXT Pharmaceuticals	$3.00 -13.3%	$92.21	$3.00 ▼ $83,758.80	$1.43M	1.9	2.35 million shs	122,999 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CANF Can-Fite BioPharma	+0.89%	+2.10%	+6.25%	+1.49%	-74.36%
CDT CDT Equity	-10.11%	-40.91%	-33.73%	-83.75%	-99.94%
JAGX Jaguar Animal Health	-6.37%	-6.64%	-16.19%	-77.19%	-98.69%
SXTC China SXT Pharmaceuticals	-13.29%	-26.83%	-28.57%	-97.75%	-99.98%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CANF Can-Fite BioPharma	$3.40 +0.9%	$3.33	$2.56 ▼ $13.40	$2.23M	1.11	988,726 shs	23,944 shs
CDT CDT Equity	$1.69 -10.1%	$4.06	$1.62 ▼ $2,739.80	$1.33M	1.52	97,100 shs	485,652 shs
JAGX Jaguar Animal Health	$0.81 -6.4%	$1.57	$0.73 ▼ $85.40	$490K	-0.06	191,029 shs	159,927 shs
SXTC China SXT Pharmaceuticals	$3.00 -13.3%	$92.21	$3.00 ▼ $83,758.80	$1.43M	1.9	2.35 million shs	122,999 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CANF Can-Fite BioPharma	+0.89%	+2.10%	+6.25%	+1.49%	-74.36%
CDT CDT Equity	-10.11%	-40.91%	-33.73%	-83.75%	-99.94%
JAGX Jaguar Animal Health	-6.37%	-6.64%	-16.19%	-77.19%	-98.69%
SXTC China SXT Pharmaceuticals	-13.29%	-26.83%	-28.57%	-97.75%	-99.98%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CANF Can-Fite BioPharma	2.67	Moderate Buy	$44.00	1,194.12% Upside
CDT CDT Equity	1.00	Sell	N/A	N/A
JAGX Jaguar Animal Health	1.00	Sell	N/A	N/A
SXTC China SXT Pharmaceuticals	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest JAGX, CANF, CDT, and SXTC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	SXTC China SXT Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
7/28/2026	SXTC China SXT Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
7/17/2026	JAGX Jaguar Animal Health	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/10/2026	SXTC China SXT Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
7/2/2026	CANF Can-Fite BioPharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$5.00 ➝ $8.00
6/25/2026	SXTC China SXT Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
6/24/2026	CDT CDT Equity	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/5/2026	SXTC China SXT Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)

(Data available from 8/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CANF Can-Fite BioPharma	$405K	5.50	N/A	N/A	$1.76 per share	1.93
CDT CDT Equity	N/A	N/A	N/A	N/A	$131.05 per share	N/A
JAGX Jaguar Animal Health	$11.51M	0.04	N/A	N/A	$8.16 per share	0.10
SXTC China SXT Pharmaceuticals	$1.14M	1.26	N/A	N/A	$2,468.59 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CANF Can-Fite BioPharma	-$7.63M	-$22.80	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CDT CDT Equity	-$39.22M	-$3,354.31	N/A	N/A	N/A	N/A	-72.25%	-55.44%	N/A
JAGX Jaguar Animal Health	-$53.43M	-$248.88	N/A	N/A	N/A	-187.88%	N/A	-131.45%	11/12/2026 (Estimated)
SXTC China SXT Pharmaceuticals	-$6.20M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest JAGX, CANF, CDT, and SXTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/19/2026	Q2 2026	JAGX Jaguar Animal Health	-$52.15	-$15.70	+$36.45	-$15.70	$4.24 million	$1.23 million
8/12/2026	Q2 2026	CDT CDT Equity	N/A	-$8.71	N/A	-$8.71	N/A	N/A
7/15/2026	Q1 2026	CDT CDT Equity	N/A	-$55.60	N/A	-$55.60	N/A	N/A
7/1/2026	Q4 2026	SXTC China SXT Pharmaceuticals	N/A	$6.84	N/A	$6.8350	N/A	$0.26 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CANF Can-Fite BioPharma	N/A	N/A	N/A	N/A	N/A
CDT CDT Equity	N/A	N/A	N/A	N/A	N/A
JAGX Jaguar Animal Health	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CANF Can-Fite BioPharma	N/A	2.93	N/A
CDT CDT Equity	N/A	0.13	0.13
JAGX Jaguar Animal Health	0.35	0.69	0.40
SXTC China SXT Pharmaceuticals	0.02	7.94	7.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CANF Can-Fite BioPharma	21.00%
CDT CDT Equity	3.29%
JAGX Jaguar Animal Health	12.04%
SXTC China SXT Pharmaceuticals	5.02%

Insider Ownership

Company	Insider Ownership
CANF Can-Fite BioPharma	0.80%
CDT CDT Equity	7.34%
JAGX Jaguar Animal Health	0.18%
SXTC China SXT Pharmaceuticals	3.95%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CANF Can-Fite BioPharma	8	655,000	N/A	Not Optionable
CDT CDT Equity	3	790,000	729,000	Not Optionable
JAGX Jaguar Animal Health	50	600,000	602,000	No Data
SXTC China SXT Pharmaceuticals	90	480,000	459,000	Not Optionable

JAGX, CANF, CDT, and SXTC Headlines

Recent News About These Companies

China SXT Pharmaceuticals (NASDAQ:SXTC) Rating Increased to Sell at Wall Street Zen

August 22, 2026 | americanbankingnews.com

Promising Chinese Stocks To Follow Now - August 16th

August 19, 2026 | americanbankingnews.com

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Sees Significant Growth in Short Interest

August 11, 2026 | marketbeat.com

China SXT Pharmaceuticals, Inc. Announces Share Consolidation

August 5, 2026 | globenewswire.com

Univest Securities, LLC Announces Closing of $9 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)

July 24, 2026 | globenewswire.com

China SXT Pharmaceuticals Raises $9 Million in Registered Direct Offering

July 24, 2026 | tipranks.com

China SXT Pharmaceuticals Enters $9 Million Registered Direct Offering of Units to Institutional Investors

July 23, 2026 | quiverquant.comQ

China SXT Pharmaceuticals Inc. Announces $9 Million Registered Direct Offering

July 23, 2026 | globenewswire.com

China SXT Pharmaceuticals Inc. Cl A

July 14, 2026 | barrons.com

China SXT Pharmaceuticals shares surge over 25% after hours: Here's why

June 2, 2026 | msn.com

China SXT Pharmaceuticals Launches $100 Million ATM Equity Program with Univest Securities

June 1, 2026 | tipranks.com

China SXT Pharmaceuticals Raises $3.5 Million in Offshore Private Placement

May 11, 2026 | theglobeandmail.com

China Sxt Pharmaceuticals, Inc. Class A

April 7, 2026 | edition.cnn.com

China SXT Pharmaceuticals, Inc. Announces Share Re-classification

March 23, 2026 | globenewswire.com

This nano-cap pharma stock crashed 30% today – what triggered the sell-off?

January 30, 2026 | msn.com

China SXT Pharmaceuticals, Inc. Announces Share Consolidation

January 30, 2026 | globenewswire.com

CHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC INITIATIVE TO APPLY AI TECHNOLOGY ACROSS THE TCM SUPPLY CHAIN

January 15, 2026 | finance.yahoo.com

Univest Securities, LLC Announces Closing of $10 Million Registered Direct Offering for its Client China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC)

January 13, 2026 | globenewswire.com

Why China SXT Pharmaceuticals, Inc.’s (SXTC) Stock Is Down 8.81%

January 11, 2026 | aaii.comA

China SXT Pharmaceuticals Inc. Announces $10 Million Registered Direct Offering

January 9, 2026 | globenewswire.com

CHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC AI INSIGHTS INITIATIVE TO OPTIMIZE TRADITIONAL CHINESE MEDICINE PORTFOLIO, ENHANCE MARKET ANALYSIS AND ...

January 8, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

JAGX, CANF, CDT, and SXTC Company Descriptions

Can-Fite BioPharma NYSE:CANF

$3.40 +0.03 (+0.89%)

As of 08/28/2026 04:00 PM Eastern

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

CDT Equity NASDAQ:CDT

$1.69 -0.19 (-10.11%)

As of 08/28/2026 04:00 PM Eastern

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.

Jaguar Animal Health NASDAQ:JAGX

$0.81 -0.06 (-6.37%)

As of 08/28/2026 04:00 PM Eastern

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

China SXT Pharmaceuticals NASDAQ:SXTC

$3.00 -0.46 (-13.29%)

As of 08/28/2026 04:00 PM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest JAGX, CANF, CDT, and SXTC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest JAGX, CANF, CDT, and SXTC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

JAGX, CANF, CDT, and SXTC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

JAGX, CANF, CDT, and SXTC Company Descriptions

Can-Fite BioPharma NYSE:CANF

CDT Equity NASDAQ:CDT

Jaguar Animal Health NASDAQ:JAGX

China SXT Pharmaceuticals NASDAQ:SXTC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest JAGX, CANF, CDT, and SXTC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest JAGX, CANF, CDT, and SXTC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

JAGX, CANF, CDT, and SXTC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

JAGX, CANF, CDT, and SXTC Company Descriptions

Can-Fite BioPharma NYSE:CANF

CDT Equity NASDAQ:CDT

Jaguar Animal Health NASDAQ:JAGX

China SXT Pharmaceuticals NASDAQ:SXTC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools